Arcellx (ACLX) Share-based Compensation (2021 - 2025)
Arcellx's (ACLX) quarterly Share-based Compensation came in at $39.5 million in Q4 2025, down 35.39% year-on-year from $61.1 million in Q4 2024, and up 1237.11% quarter-over-quarter from -$3.5 million in Q3 2025.
Arcellx (ACLX) Share-based Compensation (2021 - 2025) Analysis & Trends
Arcellx's Share-based Compensation history runs 5 years deep, the most recent figure standing at $39.5 million for Q4 2025.
- On a quarterly basis, Share-based Compensation fell 35.39% year-over-year to $39.5 million in Q4 2025; TTM through Dec 2025 was $77.9 million, a 27.51% increase from a year earlier, with the FY2025 full-year figure at $94.0 million, up 53.88% from the prior year.
- Share-based Compensation climbed to $39.5 million in Q4 2025 per ACLX's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $61.1 million in Q4 2024 and bottomed at -$31.2 million in Q4 2023.
- The 5-year median for Share-based Compensation is $5.9 million (2022), against an average of $8.4 million.
- Across the five-year window, Share-based Compensation soared 460.12% in 2022 and plunged 638.41% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $2.9 million in 2021, then jumped by 99.52% to $5.8 million in 2022, then plunged by 638.41% to -$31.2 million in 2023, then surged by 295.95% to $61.1 million in 2024, then plunged by 35.39% to $39.5 million in 2025.
- Per Business Quant, the three latest ACLX Share-based Compensation figures stand at $39.5 million (Q4 2025), -$3.5 million (Q3 2025), and $18.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 39.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.47 Mn |
| Dec 31, 2025 | 39.47 Mn |
| Sep 30, 2025 | -3.47 Mn |
| Sep 30, 2025 | -3.47 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Jun 30, 2025 | 18.08 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Mar 31, 2025 | 23.82 Mn |
| Dec 31, 2024 | 61.09 Mn |
| Dec 31, 2024 | 61.09 Mn |
| Sep 30, 2024 | -29.98 Mn |
| Sep 30, 2024 | -29.98 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Jun 30, 2024 | 15.14 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Mar 31, 2024 | 14.85 Mn |
| Dec 31, 2023 | -31.17 Mn |
| Dec 31, 2023 | -31.17 Mn |
| Sep 30, 2023 | 10.61 Mn |
| Sep 30, 2023 | 10.61 Mn |